Results 1 to 10 of about 4,608 (197)

First results and experience with PRRT in South Africa

World Journal of Nuclear Medicine, 2018
Neuroendocrine tumors (NETs) are a diverse group of tumors that often present late due to nonspecific symptoms. These tumors frequently express somatostatin receptors (SSRs), which allows for positron emission tomography/computed tomography (PET/CT ...
Mariza Vorster, M Modiselle, C Corbett, I Lawal, John Buscombe, Mike Sathekge   +5 more
doaj   +4 more sources

A case report of enduring benefit of sequential PRRT in malignant insulinoma [PDF]

EJNMMI Reports
We report the case of a 62-year-old woman diagnosed in 2015 with de novo metastatic malignant insulinoma. She presented severe hypoglycemia and was initially treated with somatostatin analogs, chemotherapy (capecitabine-temozolomide), and diazoxide, but ...
Cristina-An Wang Zhang, Natacha Driessens, Magdalena Mileva, Amélie Deleporte, Patrick Flamen, Ioannis Karfis   +5 more
doaj   +3 more sources

Molecular Deconvolution of Circulating "Other Cells": A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients Receiving ¹⁷⁷Lu-DOTATATE PRRT. [PDF]

Cancer Med
ABSTRACT Purpose To assess the prognostic impact of pre‐treatment circulating other cells on treatment response and survival in neuroendocrine tumor (NET) patients receiving Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu‐DOTATATE. Methods Healthy donors (HDs, n = 81) and NET patients (n = 137) were analyzed.
Padwal MK, Parghane RV, Basu S, Basu B.
europepmc   +3 more sources

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) [PDF]

BMC Cancer
Background Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the standard of care for well-differentiated metastatic or locally advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Ameya D. Puranik, Indraja D. Dev, Sushil Yadav, Venkatesh Rangarajan, Archi Agrawal, Sandip Basu, Vikram A. Chaudhari, Anant Ramaswamy, Vikas Ostwal, Manish S. Bhandare, Shailesh V. Shrikhande, Rahul V. Parghane, Prabhat Bhargava, Munita M. Bal, Subhash Yadav, Shraddha Patkar, Mahesh Goel, Nilendu C. Purandare, Sneha Shah, Sayak Choudhury, Suchismita Ghosh, Manikandan Venkatachalam   +21 more
doaj   +4 more sources

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors [PDF]

Pharmaceuticals
Background: α-emitting Peptide Receptor Radionuclide Therapy (α-PRRT) is emerging as a promising new generation of PRRT for neuroendocrine tumors (NETs), providing enhanced tumor cell cytotoxicity and reduced irradiation of adjacent healthy tissues due ...
Hannes Leupe, Merel Cauwenbergh, Frederik Cleeren, Jeroen Dekervel, Chris Verslype, Christophe M. Deroose   +5 more
doaj   +4 more sources

Combination Therapies with PRRT [PDF]

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
doaj   +3 more sources

Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT [PDF]

Scientific Reports, 2021
To develop predictive models of side effect occurrence in GEPNET treated with PRRT. Metastatic GEPNETs patients treated in our centre with PRRT (177Lu-Oxodotreotide) from 2019 to 2020 were considered.
F. Scalorbi, G. Argiroffi, M. Baccini, L. Gherardini, V. Fuoco, N. Prinzi, S. Pusceddu, E. M. Garanzini, G. Centonze, M. Kirienko, E. Seregni, M. Milione, M. Maccauro   +12 more
doaj   +2 more sources

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate [PDF]

European Journal of Nuclear Medicine and Molecular Imaging, 2016
After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur, particular in PRRT with (90)Y-labelled somatostatin analogues. Risk factors have been identified for increased probability of developing renal toxicity after PRRT, including hypertension, diabetes and age.
Hendrik Bergsma, Mark Konijnenberg, Wouter A. van der Zwan, Boen L.R. Kam, Jaap J.M. Teunissen, P.P.M. Kooij, Katya Mauff, Eric P. Krenning, Dik J. Kwekkeboom   +8 more
openalex   +4 more sources

Responses to medical treatment in patients with metastatic unresectable small intestinal neuroendocrine tumors - A single center study of 378 patients. [PDF]

J Neuroendocrinol
Abstract Small intestinal neuroendocrine tumors (siNET) are rare malignancies, often diagnosed at advanced stages with metastatic spread. While surgery is the only curative treatment, medical therapies, including somatostatin analogues (SSA), peptide receptor radionuclide therapy (PRRT), and other systemic treatments, are essential for disease ...
Slott C, Langer SW, Oturai P, Møller S, Hansen CP, Kjaer A, Holmager P, Klose M, Garbyal RS, Knigge U, Andreassen M.   +10 more
europepmc   +2 more sources

PRRT in NET’s: Lu-177 PRRT and New Scope Alpha Treatment

Nuclear Medicine Seminars, 2021
Seçkin Bilgiç, Emre Demirci, Nalan Alan Selçuk, Levent Kabasakal   +3 more
openalex   +2 more sources